Granules India Q2FY27 Revenue Jumps 20% YoY to ₹15,600 Million; PAT Up 39%
Granules India reported Q2FY27 revenue of ₹15,600 million, up 20% YoY. PAT increased by 39% YoY to ₹1,818 million. The company ended the quarter with ₹8,280 million in net cash. Management noted a strategic shift towards complex generics and peptide CDMO, with two new first-to-file ANDAs filed.
The substantial growth in key financial metrics and the improvement in cash position are material positive developments for the company, likely to impact investor sentiment and stock performance.
The company reported significant year-on-year growth in revenue, EBITDA, PBT, and PAT, alongside a strong improvement in net cash position, indicating positive financial performance.
Granules India Limited announced its financial results for the second quarter and half-year ended September 30, 2026. The company reported a consolidated revenue from operations of ₹15,600 million (₹1,560 crore), marking a significant 20% year-on-year growth. EBITDA stood at ₹3,376 million (₹337.6 crore), an increase of 21% YoY, while Profit Before Tax (PBT) grew by 38% YoY to ₹2,434 million (₹243.4 crore). Profit After Tax (PAT) saw a substantial rise of 39% YoY, reaching ₹1,818 million (₹181.8 crore).
For the quarter, revenue from Finished Dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides CDMO contributed 73%, 13%, 10%, and 3% of the revenue from operations, respectively. Revenue share from North America was 72% (down from 76% YoY), and from Europe it was 16% (up from 12% YoY). The company achieved a Return on Capital Employed (ROCE) of 17.6%, consistent with FY26. Granules India concluded the quarter with a net cash position of ₹8,280 million (₹828 crore), a notable improvement from a net debt of ₹1,012 million (₹101.2 crore) in Q1 FY27.
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, commented on the results, highlighting the revenue crossing ₹1,500 crore in Q2 FY27 despite higher input and logistics costs. He mentioned the filing of two potential first-to-file ANDAs in H1, bringing the total to three, and a strategic shift towards complex generics and peptide CDMO. The company also concluded a US FDA audit at the Gagillapur site, which progressed constructively, with observations that the company believes can be addressed through corrective actions.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.